European Journal of Cancer
Volume 45, Issue 1 , Pages 164-173 , January 2009

Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours

Received 12 June 2008 ,Revised 20 August 2008 ,Accepted 7 October 2008.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Lohr JM. Medical treatment of pancreatic cancer. Exp Rev Anticancer Ther. 2007;7:533–544
  3. Wang Y, Gao J, Li Z, Jin Z, Gong Y, Man X. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer. 2007;121:2716–2722
  4. Gendler SJ, Spicer AP. Epithelial mucin genes. Ann Rev Physiol. 1995;57:607–634
  5. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta. 2006;1765:189–222
  6. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45–60
  7. Chambers JA, Harris A. Expression of the cystic fibrosis gene and the major pancreatic mucin gene, MUC1, in human ductal epithelial cells. J Cell Sci. 1993;105(Pt 2):417–422
  8. Jass JR, Walsh MD. Altered mucin expression in the gastrointestinal tract: a review. J Cell Mol Med. 2001;5:327–351
  9. Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 2006;16:467–476
  10. Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobil Pancreat Surg. 2007;14:243–254
  11. Saitou M, Goto M, Horinouchi M, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol. 2005;58:845–852
  12. Kalra AV, Campbell RB. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Brit J Cancer. 2007;97:910–918
  13. Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005;18:1295–1304
  14. Shi Q, Xie K. Experimental animal models of pancreatic cancer (review). Int J Oncol. 2000;17:217–225
  15. Balkwill FR, Ward BG, Fiers W. Effects of tumour necrosis factor on human tumour xenografts in nude mice. Ciba Found Symp. 1987;131:154–169
  16. Rowlinson-Busza G, Bamias A, Krausz T, Epenetos AA. Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection. Cancer Res. 1991;51:3251–3256
  17. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol Ther. 1991;50:367–424
  18. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6:1653–1664
  19. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Brit J Cancer. 1999;80:1726–1733
  20. Fanciullino R, Evrard A, Cuq P, et al. Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. Anticancer Drugs. 2006;17:463–470
  21. Song EY, Qu CF, Rizvi SM, et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther. 2007;7:
  22. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 2008;1780:546–563
  23. Walters RW, Pilewski JM, Chiorini JA, Zabner J. Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem. 2002;277:23709–23713
  24. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65:473–482
  25. Hang HC, Bertozzi CR. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg Med Chem. 2005;13:5021–5034
  26. Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting. Pharm Res. 2006;23:2809–2817
  27. Tsutsumida H, Swanson BJ, Singh PK, et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res. 2006;12:2976–2987
  28. Choi SR, Cho M, Kim HR, Ahn DH, Sleisenger MH, Kim YS. Biological properties and expression of mucins in 5-fluorouracil resistant HT29 human colon cancer cells. Int J Oncol. 2000;17:141–147
  29. Lesuffleur T, Barbat A, Dussaulx E, Zweibaum A. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res. 1990;50:6334–6343
  30. Lafitte G, Thuresson K, Soderman O. Diffusion of nutrients molecules and model drug carriers through mucin layer investigated by magnetic resonance imaging with chemical shift resolution. J Pharm Sci. 2007;96:258–263
  31. Larhed AW, Artursson P, Bjork E. The influence of intestinal mucus components on the diffusion of drugs. Pharm Res. 1998;15:66–71
  32. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci. 1996;85:1070–1076
  33. Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv Drug Delivery Rev. 2001;48:173–193
  34. Meaney C, O’Driscoll C. Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models. Eur J Pharm Sci. 1999;8:167–175

PII: S0959-8049(08)00804-6

doi: 10.1016/j.ejca.2008.10.008

European Journal of Cancer
Volume 45, Issue 1 , Pages 164-173 , January 2009

Article Tools

* Image Usage & Resolution